# Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer

> **NCT01283789** · PHASE2 · UNKNOWN · sponsor: **University of Kansas Medical Center** · enrollment: 23 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Lapatinib and RAD-001

## Key facts

- **NCT ID:** NCT01283789
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-02
- **Primary completion:** 2016-04
- **Final completion:** 2017-04
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2017-02-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01283789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01283789, "Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01283789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*